Latest News & Features
Americas
The US Court of Appeals for the Federal Circuit has upheld a district court’s decision to invalidate a patent covering arthritis treatment Humira, after a challenge by biopharmaceutical company AbbVie. 9 April 2015
Genetics
The new CRISPR-Cas9 gene-editing system is set to revolutionise the treatment of genetic diseases, but there’s a fight to secure rights to the platform. LSIPR takes a look at the major players in this exciting technology area, and what patent disputes may arise as it develops. 9 April 2015
Americas
A US hedge fund manager and a company he created has taken aim at Jazz Pharmaceuticals in an inter partes review patent challenge, marking the third time he has challenged a company’s patents. 9 April 2015
Americas
Merck Sharp & Dohme has sued Apotex at the US District Court for the District of New Jersey for allegedly infringing a patent covering hay fever nasal spray Nasonex. 8 April 2015
Americas
US anti-cancer company Juno Therapeutics and a children’s hospital have settled their patent licensing suit with pharmaceutical business Novartis and the trustees of the University of Pennsylvania. 7 April 2015
Americas
Law firm Kramer Levin Naftalis & Frankel has hired life sciences attorneys Brian Slater and Gregory Sephton. 7 April 2015
Americas
Law firm Schiff Hardin has added Cindy Ahn as counsel in its intellectual property practice group. 2 April 2015
Americas
There are important differences between the EPO and the USPTO in the assessment of patentable subject matter in life sciences. Depending on the technology involved, patentees may elect national or regional applications as a useful alternative to PCT filings, as Joachim Wachenfeld and Oswin Ridderbusch explain. 2 April 2015
Americas
Forest Labs, a subsidiary of Actavis, has sued InvaGen for allegedly infringing four patents covering depression drug Viibryd, in what is the fifth related lawsuit. 1 April 2015
Americas
A US appeals court has overturned a district court's decision to deny Apotex's request for a declaratory judgment that its proposed generic blood pressure drug would not infringe a patent owned by pharmaceutical company Daiichi Sankyo. 1 April 2015